The pathophysiology of inorganic polyphosphates ininflammatory bowel disease.

• Conditions: HEALTHY VOLUNTEERS; K50.9; K51.9; A04.8; Crohn disease, unspecified; Ulcerative colitis, unspecified; Other specified bacterial intestinal infections

• Registration Number: DRKS00023079
• Lead Sponsor: Medizinische Universität Graz

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-11
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

Written informed consent, pediatric patients suspicious for CED or bacterial intestinal infection or volunteers (healthy and normal clotting and aggregation tests)

Exclusion Criteria

missing written consent, anticoagulant therapy (e.g. Heparin) or antiplatelet therapy (e.g. Aspirin or Clopidogrel)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome is the concentration of inorganic polyphosphates in plasma.

Secondary Outcome Measures

Name	Time	Method
Secondary outcome is the levels of polyphosphates in platelets and stools.